MedTrace Logo

Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis

NCT00279162 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-02-24

No results posted yet for this study

Summary

Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patients will receive an ointment containing both calcipotriene plus betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.

The objective is to study the short-term efficacy of the gel, and the short and long-term safety of the gel and the ointment.

Conditions

Interventions

DRUG

Calcipotriene/betamethasone gel and ointment

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • S Tyring, MD · Center for Clinical Studies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00279162 on ClinicalTrials.gov